Mequinol API Manufacturers

General Description:

Mequinol, identified by CAS number 150-76-5, is a notable compound with significant therapeutic applications. Mequinol is a phenol used in various applications. It is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture of antioxidants, pharmaceuticals, plasticizers, and dyestuffs . It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.

Indications:

This drug is primarily indicated for: Mequinol is currently primarily available only as an active ingredient in combination products combined with tretinoin that are indicated for the treatment of solar lentigines and related hyperpigmented lesions resulting from chronic sun exposure . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Mequinol undergoes metabolic processing primarily in: Urine samples from melanoma patients treated with mequinol were analyzed and various mequinol metabolites were identified, including 3,4-dihydroxyanisole, the two o-methyl derivatives 3-hydroxy-4-methoxyanisole and 4-hydroxy-3-methoxyanisole, and even hydroquinone which may have originated at least partly from mequinol . All these identified metabolites were excreted predominantly as sulphates and glucuronides - only a small portion of the substances were present in urine in an unconjugated form . Ultimately, the 3,4-dihydroxyanisole is considered the most important metabolite of mequinol . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Mequinol are crucial for its therapeutic efficacy: The systemic exposure to mequinol was assessed in eight healthy subjects following two weeks of twice-daily topical treatment of a tretinoin and mequinol combination product . About dose of the product corresponding to about 37.3 ug/cm^2 of mequinol was applied to the subjects' backs . The mean Cmax for mequinol was 9.92 ng/mL (range between 4.22 and 23.62 ng/mL) and the Tmax was 2 hours (range between 1 to 2 hours) . The safety of mequinol in this combination formulation is supported by the low systemic exposures of the agent in the subjects . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Mequinol is an important consideration for its dosing schedule: Mequinol demonstrated an elimination half-life of 30 to 90 minutes following intravenous infusion of 5 or 10 grams/m^2 over 3 to 5 hours in melanoma patients; similar values were reported after intra-arterial infusion . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Mequinol exhibits a strong affinity for binding with plasma proteins: Readily accessible data regarding the protein binding of mequinol is not available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Mequinol from the body primarily occurs through: Mequinol is predominantly renally eliminated as its metabolites . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Mequinol is distributed throughout the body with a volume of distribution of: The volume of distribution is one that suggests mequinol is distributed throughout the total body water, and intracellular concentrations are not expected to vary greatly from gross measurements . This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Mequinol is a critical factor in determining its safe and effective dosage: Readily accessible data regarding the clearance of mequinol is not available. The use of mequinol containing products is typically indicated for topical use. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Mequinol exerts its therapeutic effects through: Mequinol is in fact considered a melanocytotoxic chemical which when oxidized in melanocytes results in the formation of toxic entities like quinones . Such cytotoxic compounds subsequently have the potential to damage and destroy pigment cells, therefore causing skin depigmentation . In response, skin cells are naturally capable of protecting themselves against such cytotoxic agents with the help of endogenous intracellular glutathione and the detoxification action of glutathione S-transferase on the cytotoxic compounds . Regardless, it is consequently by way of this seemingly negative and damaging pharmacodynamic profile by which the mechanism of action of mequinol is sometimes described . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Mequinol functions by: Solar lentigines and related hyperpigmented lesions are localized, pigmented, macular lesions of the skin, usually on the areas of the body which have been chronically exposed to sunlight . These lesions are characterized by increased numbers of active melanocytes and increased melanin production . Although the mechanism of action of mequinol is not fully elucidated , when employed as an active ingredient in combination with other agents like tretinoin in skin depigmentation products, a synergy between a number of potential mechanisms is proposed. Firstly, mequinol is in fact considered a melanocytotoxic chemical which when oxidized in melanocytes results in the formation of toxic compounds like quinones . Such cytotoxic agents are subsequently capable of damaging and destroying pigment cells, which results in skin depigmentation of solar lentigines or other related hyperpigmented lesions. Nevertheless, skin cells are naturally capable of protecting themselves against such cytotoxic entities by endogenous intracellular glutathione (GSH) . This protection is elicited through the enzymatic action of glutathione S-transferase (GST), which is responsible for the conjugation of agents toxic to glutathione . Conversely, tretinoin has been observed to serve as a potent inhibitor of mammalian GSTs and to be capable of reducing the level of intracellular GSH in various cells . As a result, the combination of mequinol with tretinoin seemingly allows for a synergistic enhancement of a melanocytotoxic effect that involves the inhibition and impairment of GSH and GST cytoprotection . Secondly, even though mequinol is a substrate for the enzyme tyrosinase and therefore acts as a competitive inhibitor of the formation of melanin precursors by way of tyrosinase facilitated reactions, the clinical significance of this action is unknown . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Mequinol belongs to the class of organic compounds known as methoxyphenols. These are compounds containing a methoxy group attached to the benzene ring of a phenol moiety, classified under the direct parent group Methoxyphenols. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Phenols class, specifically within the Methoxyphenols subclass.

Categories:

Mequinol is categorized under the following therapeutic classes: Antioxidants, Benzene Derivatives, Biological Factors, Compounds used in a research, industrial, or household setting, Depigmenting Agents, Dermatologicals, Ethers, Lentigo, Melanin Synthesis Inhibitors, Methyl Ethers, Phenols, Phenyl Ethers, Protective Agents, Skin Lightening Agent. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.